TITLE

Financings roundup

PUB. DATE
October 2007
SOURCE
Medical Device Daily;10/10/2007, Vol. 11 Issue 194, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Optherion, a company developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, has raised $37 million in start up financing. The company plans to develop disease-modifying therapies to prevent loss of vision in patients with dry AMD.
ACCESSION #
27025344

 

Related Articles

  • Optherion's Protein Replacement For AMD Nabs $37M Series A. Morrison, Trista // BioWorld Today;10/10/2007, Vol. 18 Issue 197, p1 

    The article reports on the amount raised by New Haven, Connecticut-based Optherion Inc. from a Series A financing. The company raised $37 million to advance its preclinical research with a new approach to diagnosing and treating age-related macular degeneration (AMD). The company is pursuing the...

  • Optherion wins protection from Canada for AMD diagnostics.  // Diagnostics & Imaging Week;5/7/2009, Vol. 12 Issue 18, p3 

    The article announces that the Canadian Patent Office has granted Optherion patents 2,363,503 and 2,407,715. The patents offer protection for diagnostic tests to identify the predisposition to age-related macular degeneration (AMD) by screening for genetic modificaitons in various genes such as...

  • Sequenom acquires rights to Optherion's AMD genetic tests.  // Medical Device Daily;2/10/2010, Vol. 14 Issue 27, p3 

    The article reports on the exclusive worldwide licensing agreement reached by Sequenom with Optherion in February 2010. It states that the deal will allow the Sequenom Center for Molecular Medicine the rights to manufacture and market diagnostic tests to predict genetic predisposition to late...

  • Optherion's AMD Drug Nabs $37M Series A.  // Bioworld Week;10/15/2007, Vol. 15 Issue 42, p3 

    The article reports that Optherion Inc. in Connecticut has raised $37 million in a Series A round to further preclinical research with a new approach for the diagnosis and treatment of age-related macular degeneration (AMD). Optherion focuses on genetic mutations in Complement Factor H, which...

  • Lutein and zeaxanthin for macular degeneration. Zhao, Lili; Sweet, Burgunda V. // American Journal of Health-System Pharmacy;7/1/2008, Vol. 65 Issue 13, p1232 

    Purpose. The effects of increasing lutein and zeaxanthin dosages in people with age-related macular degeneration (AMD) are discussed. Summary. AMD is a disorder of the macula, the area associated with the sharpest visual acuity. AMD is classified as dry (nonneovascular) or wet (neovascular) and...

  • Antioxidant Drug Therapy Approaches for Neuroprotection in Chronic Diseases of the Retina. Payne, Andrew J.; Kaja, Simon; Naumchuk, Yuliya; Kunjukunju, Nancy; Koulen, Peter // International Journal of Molecular Sciences;Feb2014, Vol. 15 Issue 2, p1865 

    The molecular pathways contributing to visual signal transduction in the retina generate a high energy demand that has functional and structural consequences such as vascularization and high metabolic rates contributing to oxidative stress. Multiple signaling cascades are involved to actively...

  • Identification of the first AHI1 gene mutations in nephronophthisis-associated Joubert syndrome. Boris Utsch; Sayer, John A.; Attanasio, Massimo; Pereira, Rob Rodrigues; Eccles, Michael; Hennies, Hans-Christian; Otto, Edgar A.; Hildebrandt, Friedhelm // Pediatric Nephrology;Jan2006, Vol. 21 Issue 1, p32 

    Joubert syndrome (JBTS) is an autosomal recessive multisystem disease characterized by cerebellar vermis aplasia, mental retardation, muscular hypotonia, an irregular breathing pattern in the neonatal period and abnormal eye movements. Some individuals have progressive renal failure...

  • Alcon rings NYSE bell; anecortave trials begin.  // Ophthalmology Times;1/1/2004, Vol. 29 Issue 1, p6 

    Reports that Tim Sear, Alcon Inc.'s chairman, president and chief executive officer, rang the closing bell of the New York Stock Exchange at 4 pm December 4, 2003 to celebrate the company's dramatic rise in stock price since its initial public offering. Completion of a partial IPO in March 21,...

  • Regeneron Stock Up 19.7% After Positive VEGF Trap-Eye Report. Wall, Tom // BioWorld Today;11/23/2010, Vol. 21 Issue 227, p1 

    The article reports that stock price in Regeneron Pharmaceuticals Inc. increased by 4.86 U.S. dollars to 29.53 U.S. dollars following the release of data from the company and partner Bayer HealthCare on two parallel Phase III studies of VEGF Trap-Eye. Primary endpoints were met in the trials...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics